Trauma-induced melanocyte implantation can lead to subcutaneous melanoma, mimicking melanoma of unknown primary but with distinct diagnostic criteria.
2025
Dr Sullivan on RP1 Plus Nivolumab in Anti–PD-1–Refractory Melanoma
Ryan Sullivan, MD, director, Center for Melanoma, Massachusetts General Hospital, discusses findings from the phase 2 IGNYTE trial (NCT03767348) evaluating RP1 in combination with nivolumab (Opdivo) in patients with advanced melanoma who progressed on prior anti–PD-1 therapy.
Post–PD-1 Data in Melanoma Offers Insight into IO Approaches
During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed goals and barriers to treatment when using combination immunotherapy for metastatic melanoma in the second article of a 2-part series.
Nivolumab Plus Relatlimab Fails to Improve RFS in Resected Stage III/IV Melanoma
Nivolumab plus relatlimab did not improve recurrence-free survival vs nivolumab in resected stage III/IV melanoma.